drugset / Trial / NCT00084227

Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America

NCT00084227

Phase 2/3 Completed 244 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective is to confirm the hypothesis that azithromycin plus chloroquine is non-inferior to atovaquone-proguanil for the treatment of symptomatic, uncomplicated malaria due to P. falciparum.

Timeline

Start
2004-07
Primary completion
Completion
2005-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Atovaquone Small molecule
Subject Azithromycin Small molecule
Subject Chloroquine Small molecule
Subject Proguanil Small molecule